Myocarditis Clinical Trial
— MYCOVACCOfficial title:
MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study
NCT number | NCT06103123 |
Other study ID # | MYCOVACC |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 23, 2023 |
Est. completion date | April 23, 2025 |
Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection. The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | April 23, 2025 |
Est. primary completion date | March 23, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Inclusion criteria for vaccine associated myocarditis/pericarditis. 1. COVID-19 vaccination within previous 42 days. AND 2. At least one cardiac symptom of suspected myocarditis/pericarditis (Appendix 5). OR At least two non-specific symptoms (Appendix 5). OR In infants and young children, at least two non-specific pediatric symptoms (Appendix 5). OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI). AND 3. At least one of the following objective findings (Brighton Criteria case definitions, Appendices 1 to 5): 1. Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation. 2. Elevated myocardial biomarker (Troponin T, Troponin I, or CK-MB). 3. Cardiac MRI abnormality. 4. Echocardiographic abnormality. 5. New or worsening arrhythmia on electrocardiogram, Holter monitor, or telemetry. 6. Elevated inflammation biomarkers: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hs-CRP, or D-Dimer. 7. Physical examination pericardial friction rub or pulsus paradoxus. 8. Pericardial fluid or inflammation by imaging (echo, MRI, or CT). 9. Enlarged heart on chest radiograph. AND 4. No alternative cause of presentation. e.g. infectious or autoimmune myocarditis. - Inclusion criteria for COVID-19 associated myocarditis/pericarditis 1. COVID-19 infection within the previous 42 days. AND 2. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis. AND 3. No alternative cause of presentation. Inclusion criteria alternative etiology myocarditis. 1. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis. AND 2. No alternative cause of presentation. Exclusion Criteria: - For prospective invitation and follow-up, inability to provide informed consent. Consent will be sought from patients or their authorised substitute decision maker. - Patients not fulfilling Brighton Criteria levels 1-3 will be excluded if they are level 4 (insufficient evidence for myocarditis) or Level 5 (not myocarditis) or have an alternative diagnosis such as myocardial infarction. |
Country | Name | City | State |
---|---|---|---|
Canada | Vancouver General Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
Cardiology Research UBC |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite Major Adverse Cardiac Event (MACE) at 30 days post vaccination (preferred by cardiovascular community) and at 42 days post vaccination (preferred by vaccine monitoring investigators) | Including any of:
Death from any cause. Ventricular arrhythmia (ventricular fibrillation or ventricular tachycardia). Heart block (type II or type III block). Heart failure (national guideline criteria). Left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] <55%). Cardiac tamponade. |
From date of vaccination and up to 3 years | |
Primary | Recovery of cardiac function in patients with previously documented abnormal cardiac function | Patients with Left Ventricular Ejection Fraction (LVEF)<55% during anytime at baseline, with LVEF increase by 5% from worst baseline measurement | Through study completion, an average of 3 years | |
Primary | Quality of life using validated instruments at baseline, 3 months, 12 months, and annually | Quality of life: EQ-5D-5L questionnaire for adults or EQ-5D-Y questionnaire for children. | Through study completion, an average of 3 years | |
Primary | Depression and anxiety using validated instruments at baseline, 3 months, 12 months, and annually | Depression and anxiety data: PHQ-9 and GAD-7. | Through study completion, an average of 3 years | |
Primary | Physical activity using validated instruments at baseline, 3 months, 12 months, and annually | Physical activity: International Activity Questionnaire. | Through study completion, an average of 3 years | |
Secondary | Individual components of primary composite endpoint at 30 days and 42 days post mRNA COVID-19 vaccination? | From date of vaccination for up to three years | ||
Secondary | Rate of atrial arrhythmias after mRNA COVID-19 vaccination? | From date of vaccination for up to three years | ||
Secondary | Rate of all-cause and cardiovascular mortality after mRNA COVID-19 vaccination? | From date of vaccination for up to three years | ||
Secondary | Rate of all-cause and cardiovascular hospitalization after mRNA COVID-19 vaccination? | From date of vaccination for up to three years | ||
Secondary | Rate of recurrence of myocarditis/pericarditis after mRNA COVID-19 vaccination? | From date of vaccination for up to three years | ||
Secondary | Rate of constrictive pericarditis after mRNA COVID-19 vaccination? | From date of vaccination for up to three years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05911386 -
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
|
||
Not yet recruiting |
NCT04085718 -
FDG-PET/CT Images Comparing to MRI and Endomyocardial Biopsy in Myocarditis
|
||
Enrolling by invitation |
NCT05610423 -
Covid-19 Vaccine Associated Myocarditis and Pericarditis in Norway
|
||
Active, not recruiting |
NCT05195645 -
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
|
Phase 2 | |
Recruiting |
NCT05184114 -
Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance
|
N/A | |
Recruiting |
NCT04612296 -
The Heart Hive - Cardiomyopathy Study
|
||
Recruiting |
NCT04673409 -
CMR Imaging of Autoimmune Diseases
|
||
Recruiting |
NCT05295290 -
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
|
Phase 4 | |
Completed |
NCT03777839 -
PET-FDG in Myocarditis
|
||
Completed |
NCT06447935 -
Acute Eosinophilic Myocarditis International Registry
|
||
Not yet recruiting |
NCT05125965 -
Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy
|
N/A | |
Active, not recruiting |
NCT04444128 -
IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
|
||
Recruiting |
NCT06158698 -
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
|
Phase 3 | |
Recruiting |
NCT05288426 -
Myocarditis Post Vaccination or Multi System Inflammatory Syndrome
|
||
Recruiting |
NCT05282498 -
Pathophysiologic Mechanism for MYOcarditis in COVID19 VAccinations ("MYOVAx" Study)
|
||
Recruiting |
NCT03801681 -
ARrhythmias in MYocarditis
|
||
Recruiting |
NCT06116084 -
Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine
|
N/A | |
Completed |
NCT04413071 -
Cardiac COVID-19 Health Care Workers
|
||
Recruiting |
NCT05414162 -
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
|
||
Recruiting |
NCT06409585 -
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
|